J Breast Cancer.  2018 Dec;21(4):468-470. 10.4048/jbc.2018.21.e59.

The Open Issues Regarding Cyclin-Dependent Kinase 4/6 Inhibitors in the Management of Advanced Breast Cancer

• Rossi L

• KMID: 2429827
• DOI: http://doi.org/10.4048/jbc.2018.21.e59

Abstract

No abstract available.

MeSH Terms

Breast Neoplasms*
Breast*
Phosphotransferases*
Phosphotransferases

Reference

1. Choo JR, Lee SC. CDK4-6 inhibitors in breast cancer: current status and future development. Expert Opin Drug Metab Toxicol. 2018; 14:1123–1138.

2. Clinical practice guidelines in oncology: breast cancer. version 4.2017. National Comprehensive Cancer Network;Accessed February 7th, 2018. http://www.nccn.org/.

3. Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann Oncol. 2018; 29:1634–1657.

4. DeMichele A, Chodosh LA. “Braking” the cycle of resistance in endocrine therapy for breast cancer. Clin Cancer Res. 2015; 21:4999–5001.

5. Lenihan C, Bouchekioua-Bouzaghou K, Abdulghani R, Chupin J, Shia A, Schmid P. CDK4/6 inhibitor resistant ER-positive cells remain dependent on estrogen signalling and retain sensitivity to endocrine therapy. In : 40th Annual San Antonio Breast Cancer Symposium; 2016. Abstract #P3-03-12.

6. Kalinsky K, Mundi PS, Chiuzan C, Accordino MK, Trivedi MS, Sparano JA, et al. A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer. J Clin Oncol. 2017; 35:15 Suppl. TPS1112.

7. Bardia A, Hurvitz S, Yardley DA, Zelnak A, DeMichele A, Clark AS, et al. TRINITI-1: Ribociclib + everolimus (EVE) + exemestane (EXE) triplet combination in men or postmenopausal women with HR+, HER2− advanced breast cancer (ABC) following progression on a cyclin-dependent kinase (CDK) 4/6 inhibitor. Cancer Res. 2017; 77:4 Suppl. OT2-01-05.

8. Zhang J, Xu K, Liu P, Geng Y, Wang B, Gan W, et al. Inhibition of Rb phosphorylation leads to mTORC2-mediated activation of Akt. Mol Cell. 2016; 62:929–942.

9. Finn RS, Crown JP, Ettl J, Schmidt M, Bondarenko IM, Lang I, et al. Efficacy and safety of palbociclib in combination with letrozole as firstline treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. Breast Cancer Res. 2016; 18:67.

10. Cardoso F, Villanueva C, Royce M, Cruz F, Debled M, Hegg R, et al. Everolimus (EVE) plus endocrine therapy in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (BC): first- and second-line data from the BOLERO-4 study. J Clin Oncol. 2017; 35:15 Suppl. 1010.

11. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer. 2011; 11:558–572.

12. Goel S, Wang Q, Watt AC, Tolaney SM, Dillon DA, Li W, et al. Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors. Cancer Cell. 2016; 29:255–269.